Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Apologies if this has already been posted:
https://scitechdaily.com/scientists-discover-how-omega-3-battles-heart-disease-at-the-molecular-level/
Return it and ask for your brand if your script is for CVD reduction. If you were not notified like me, file a fraud complaint against your insurance company with your state Attorney General. Right now I am waiting for my doctor to fill out their brand cost difference exception form. If they mess with me after that I am writing a complaint to the AG’s office, better business and my state and federal representatives. Even if it is covered I am calling the law firm representing Amarin in the patent suit on Friday.
Great, if we can get a class action going you can join the party.
There has to be some sort of rebate because when I call my pharmacy the price for V is $20 less than the generic.
I think we have a class action of fraud against CVS Caremark as they did this to me on both FEP BCBS and now trying the same crap with Aetna. Not to mention wasting and increasing medical costs by making medical staffs fill out forms they don’t plan to honor. Maybe another suit as shareholders if we can prove the generics paid the PBM to cover their drug over the brand and violate the patent.
Does anyone have the name and location of the law firm representing Amarin in the Hikma patent lawsuit? The name of the lawyer will also be helpful. I want to call them and tell them of my direct experience with CVS Caremark and volunteer to testify on their blatant disregard for the CVD label.
File a complaint with your state attorney general as a consumer fraud complaint. You signed up with V coverage and now they are switching you to a product not approved for your condition. We need to push consumer actions on these crooks and with election season upon us, maybe someone will take action.
It’s the lag from approval to reimbursements that keeps the stock from running. I am not sure how long until you see access to the wider Chinese market but the EU reimbursement rollout has been slow. In my opinion we need two other catalysts for the stock to run. The first is the anti trust BS suit which will cause a buyer to pause due to the legal risk. The second is to get wider reimbursement. Of course if Amarin were to actually come out with another version of V to win back the US then we could see some immediate improvement. I still don’t see any strategy with this company.
Here is a good article that explains the reimbursement process in China. It does not give a timeline but is thorough.
https://search.app/1H9eVUYDJewWcKws9
Is there a reason why this action is just not added to the anti trust suit which is scheduled this fall? I sure hope we get a positive ruling on the infringement appeal and we can add these dirt bags to the suit.
Best way to end the slide is buy back as many shares and sell them to a large pharma at a premium who is willing to partner on the combo pill or once a day. We need something that will dominate the US market and I just don’t understand why they have not pivoted to a new product. A partner that has a strategic investment will make it easier to work through details with the FDA. Once the product is approved the partner can buy them out and will have lowered the acquisition cost with the initial investment.
Capt, CVS Caremark was the entity that denied me under BCBS. They argue the labels are the same. It’s my fault for not going to the state AG. They drove my doctor nuts and I was close to open enrollment I just switched. If they try again I am just going scorched earth. I still think Marjac might have a fraud case with them forcing CVD patients to switch to the non approved indication.
How is this not blatant inducement with all the directions to switch without regards to the patient condition .
Anyone affected by this should file a complaint to their state AG. The generic nor the insurance company can say it is approved for CVD risk reduction.
I have Aetna Feds and have not been notified of any change and I doubt they would do it in July when open enrollment is late November. They would drop it 1/01 like BCBS.
If anyone can post the actual PBM who is dropping V maybe we can ask Marjac if we have a shareholder case for theft of IP by the PBM. Or maybe we can find impacted insurance holders and possibly see if there is a fraud class action.
I just hope we get a favorable ruling from the circuit court and sue them all.
What PR statement I don’t see it?
See the study results, the story the way it’s written is misleading. If I went by the vital study I should just take Omacor. https://www.vitalstudy.org/findings.html
Please, when Bio Bills family posts the link for donations to his kids college fund as mentioned in the obituary please let us know. I will miss him and may god bless his soul and look over his family.
Exactly, I am not aware of any OTC study to show any significant reduction in CVD risk other than Reduce It. It’s misleading, confusing and in my opinion, would lead a reader who has CVD risk to believe OTC fish oil is fine to use.
Misleading article from Time magazine that could use your perspective and correction. They are clearly referencing Reduce it results yet referring to it as fish oil supplements. I think many on this board are better at writing to the editor than me.
https://apple.news/AjvVVNJqrRQmb7o56rqRNXA
The reference for heart patients is mid way through the article.
For federal employees looking to maximize V savings….. after the BS I went through with BCBS I switched to Aetna. The copay for Vascepa on Aetna is $20.00 for a 90 day supply and with the savings card the total cost is zero. Next open enrollment you should check Aetna.
Thanks Captain I will post it this evening and mention the generic form of IPE is not approved for CVD risk reduction nor are they tested for oxidation.
Or should I say something else…. They seemed to be pushing the generic.
Captain, let me know if you can access this article from consumer labs on fish oil supplements. Only someone with your deep knowledge can set them straight. I saw a few recommendations made by them to be genuinely inadequate on this subject.
https://www.consumerlab.com/reviews/fish-oil-supplements-review/omega3/
Maybe this will help Amarin chip away at all those wasted lovazza prescriptions.
Did you file a complaint with OPM? If they get enough complaints they might actually do something.
LB, I switched to Aetna and my co pay for 90 days through Blink RX is zero. So glad I switched after fighting with them for a year.
We might need a letter writing campaign to Congress requesting safety tests and they can charge the generic companies for the tests.
I agree and was thinking the same thing and if I recall correctly, as a board we were looking into funding some lab tests. I think we concluded Amarin probably did this already and found nothing. Then again I/we could be wrong and I doubt anyone in the company will tell us.
I was hoping we could somehow get a class action suit for fraud if their formulation was found to be inferior. The only way to make them go away is to have them suffer a court loss or a big regulatory blow up….. a recall for product quality or someone actually tests their IPE and finds issues.
Thank you for posting those comments. I suspect the area of risk right now and the reason why pharma is staying away from Amarin is the anti trust suit. A crazy decision and the buyer can lose the entire value of the company. I think once that is done, and assuming it is positive to neutral to Amarin things will heat up. I just wish we had something to screw DRL and Hikma. I still think one might have a consumer fraud suit if their drug has any oxidation.
We are less than 2 months away from knowing whether they will be able to grow the US market with the current product. Win the appeal and it’s game on, get some enforceable boundaries and they will increase sales. I still want to hear if they have plans for the once a day version or combo pill. Those restore the CVD indication from generics.
Congratulations, I have the same thing that is monitored ever 2 years and 10 years running, no progression of plaque.
I switched from those MFers at BCBS to Fed Aetna and now pay nothing through for a 30 day supply through Blink.
You need a script and not sure why a doctor would say no if you are taking OTC. Better off taking V and reducing the pills you take to match the OTC dose.
You still need a prescription for V but blink does not carry generic V.
Some of you who are posting about the OTC EPA you are buying might consider using BlinkRX. A 30 day supply of Vascepa without insurance is only $99.00 with free shipping.
Hi Captain, you will definitely be better than me to respond to the author of this review. If you can’t reply to it send it to me and I will post it. I subscribe to this publication.
https://www.consumerlab.com/reviews/fish-oil-supplements-review/omega3/
One thing they have wrong is comparing the price of V to generic. Last I checked V is cheaper and those without insurance can get a 30 day supply for $99 at BlinkRx.
Unbelievable, for some that may remember Fep BCBS refused to cover V so I switched to Aetna Feds where V is preferred brand and covered. Just called blink to reorder and my co pay is only $10 and with the savings card I pay zero. Every Fed employee taking V should switch to Aetna next year.
No, the FEP portion of Blue will not cover V, only generic. Aetna Feds has V as the preferred brand so I switched.
Good news for you and it looks like coverage is expanding.
What plan are you on? I switched from Fed BCBS to Aetna to get V coverage. I was paying $99 per month to Blink.